The Zacks Medical-Drugs industry is showing promising trends in 2024 amid strong M&A activity and positive pipeline news. Concerns around the economy and inflation, regular pipeline setbacks, uncertainty about the impact of Medicare drug price negotiations and the Federal Trade Commission’s (FTC) scrutiny of M&A deals are some of the headwinds faced by drug/biotech companies.However,innovation is at its peak for the industry, with key spaces like diabetes/obesity, inflammation and neuroscience attracting at ...